IP Creation Can Make India the Next Global Innovation Hub

In today’s world, technology is playing a transformational role in enabling innovation and driving change. New ideas, new business models and new technologies are leading to the birth of the “ideas economy,” where the “innovation quotient” has emerged as the key determinant of market value. India will lose out on the opportunity to benefit from innovation-led, … Continue reading IP Creation Can Make India the Next Global Innovation Hub

Why FY14 was a Remarkable Year for Biocon

The fiscal year gone by has been one of the most exciting ones for Biocon. We delivered on our promise of affordable innovation, recorded robust top line and bottom line growth, augmented our capacities, optimized our product portfolio and introduced initiatives to achieve operational efficiencies. We successfully commercialized two world-class, low-cost monoclonal antibodies, an outcome … Continue reading Why FY14 was a Remarkable Year for Biocon

Women at Work: Biocon Founder on Philanthropy, Sexism and Politics

In the first in a series of interviews with women who are leaders in their field in India, The Wall Street Journal’s India Real Time met Kiran Mazumdar-Shaw, the founder of biotechnology company Biocon Ltd. 532523.BY +0.16%, and one of India’s richest women. Last month, Ms. Mazumdar-Shaw was named by Forbes as one of the most generous people in Asia. … Continue reading Women at Work: Biocon Founder on Philanthropy, Sexism and Politics

Indian pharma companies need to be surefooted in their approach to quality

By Kiran Mazumdar Shaw The hefty fine that Ranbaxy Laboratories will pay as part of the drug safety settlement in the US threatens to seriously erode its reputation that can take years to regain. This is particularly sad as Ranbaxy has been a leader and stalwart among Indian generic drug makers that have, over the … Continue reading Indian pharma companies need to be surefooted in their approach to quality